Biotech · Private company · Sykesville, MD, US
Antidote Therapeutics, Inc
Track this companyFree. Adds Antidote Therapeutics, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ATI-1013 (0.2 g)Phase 1 · Thromboangiitis Obliterans (Buerger's Disease)ClinicalTrials.gov · fetched Nov 12, 2026
- ATI-1013 (0.8 g)Phase 1 · Thromboangiitis Obliterans (Buerger's Disease)ClinicalTrials.gov · fetched Nov 12, 2026
- ATI-1013 (3.2 g)Phase 1 · Thromboangiitis Obliterans (Buerger's Disease)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy SmokersPHASE1 · RECRUITING · started Oct 1, 2025ClinicalTrials.gov NCT07215923 · fetched Nov 12, 2026
NIH awards2
- IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal AntibodyFiscal year 2025 · $3.9MNIH RePORTER 5U01DA058547-03 · fetched Nov 12, 2026
- IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal AntibodyFiscal year 2024 · $5.2MNIH RePORTER 5U01DA058547-02 · fetched Nov 12, 2026